A Subject Treatment Preference Study of Tivozanib Hydrochloride Versus Sunitinib in Subjects With Metastatic Renal Cell Carcinoma (TAURUS)

A Subject Treatment Preference Study of Tivozanib Hydrochloride Versus Sunitinib in Subjects With Metastatic Renal Cell Carcinoma (TAURUS)

Sponsors and Collaborators
AVEO Pharmaceuticals, Inc.
Astellas Pharma Inc

Contact
Dajana Cesic, MD
617-299-5787
dcesic@aveooncology.com

Brooke Esteves, RN
617-299-5993
besteves@aveooncology.com

ClinicalTrials.gov Identifier
NCT01673386

Loading links....
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters